Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment

By Chris Wack

Sage Therapeutics Inc. and Biogen Inc. said they saw positive topline results from a Phase 2 study evaluating SAGE-324 in the treatment of people with essential tremor.

The companies said the study achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in the Essential Tremor Rating Assessment Scale upper limb tremor score on day 29.

Activities of daily living scores showed a statistically significant correlation with upper limb tremor score at all timepoints. SAGE-324 was numerically superior to placebo at all time points. Reported treatment-emergent adverse events were generally consistent with the safety profile of SAGE-324 to date.

The companies are planning next steps for development of SAGE-324.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

04-12-21 0738ET